Incyte Leadership

Incyte Corporation's executive management team includes accomplished leaders with deep and broad industry experience. Led by Chairman, President, and Chief Executive Officer Hervé Hoppenot, Incyte currently employs more than 900 people across our locations in the United States and Europe.

 

Image of Hervé Hoppenot, Incyte Corporation’s Chairman, President and Chief Executive Officer

Hervé Hoppenot

Chairman, President, and Chief Executive Officer

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8000 employees in 50 countries. Mr Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr Hoppenot holds a diploma from ESSEC Business School.

Image of Jonathan E. Dickinson, Incyte Corporation’s Senior Vice President, General Manager, Europe

Jonathan E Dickinson

Senior Vice President, General Manager, Europe

Jonathan Dickinson joined Incyte as Senior Vice President and General Manager, Europe in June 2016. Mr Dickinson joined Incyte from ARIAD Pharmaceuticals (Europe) Sàrl where he most recently held the position of Senior Vice President and General Manager, Europe. Prior to ARIAD, Mr Dickinson served as European oncology brand lead at Bristol-Myers Squibb and before that, he held several key leadership positions, including lifecycle leader, during his 13-year tenure at Hoffmann-La Roche. At Roche, he had assignments both in the United States and Switzerland that included leadership roles for Roche's three leading oncology medicines. Mr Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom. Mr Dickinson received his Bachelor of Science degree in Genetics and his MBA degree from the University of Nottingham.

Image of Lothar H Finke, MD, PhD, Head of Clinical Development and General Manager Japan.

Lothar H Finke, MD, PhD

Head of Clinical Development and General Manager, Japan

Lothar H Finke joined Incyte in June 2017 as General Manager of Incyte Japan, establishing the Company’s corporate presence in Asia. Dr Finke joined Incyte with over 20 years of biotech and pharmaceutical industry experience in roles of increasing responsibility at Merck KGaA, Argos Therapeutics, and Novartis Oncology with assignments in Europe, North America, and Asia. Prior to joining Incyte, Dr Finke most recently led clinical development and medical affairs for Novartis Pharma KK’s oncology-hematology portfolio at their head office in Tokyo. Dr Finke’s clinical background is in surgical oncology, having earned a medical degree and doctorate degree in cell biology from the University of Marburg, Germany.

Image of Barry p. Flannelly, Pharm.D., MBA Incyte Corporation’s Executive Vice President, General Manager U.S.

Barry P Flannelly, PharmD, MBA

Executive Vice President, General Manager, US

Barry Flannelly joined Incyte as Executive Vice President, Business Development and Strategic Planning in August 2014 and was appointed General Manager, US in June 2015. Dr Flannelly has been working in oncology since 1987, and began his career in the pharmaceutical and biotech industry at Rhone-Poulenc Rorer, which later became Sanofi-Aventis. He has since had roles of increasing responsibility at Novartis Pharmaceuticals Corporation, Abraxis Oncology, Onyx Pharmaceuticals, Inc., and Nektar Therapeutics. During his career, he has held positions in medical affairs, strategic planning, and commercial operations, including head of sales, head of marketing, and business development. He earned his Doctor of Pharmacy from the University of Maryland School of Pharmacy, his Master in Business Administration from the University of Baltimore, and his Bachelor of Science in Pharmacy from Massachusetts College of Pharmacy.

Image of David W. Gryska Incyte Corporation’s Executive Vice President, Chief Financial Officer

David W Gryska

Executive Vice President, Chief Financial Officer

David Gryska joined Incyte as Executive Vice President and Chief Financial Officer in October 2014 and brings more than 30 years of finance experience to the company. Before joining Incyte, Mr Gryska served as Chief Financial Officer at both Celgene Corporation and Scios, Inc. From 1982 to 1993, Mr Gryska worked at Ernst &Young, LLP. Mr Gryska is a CPA and earned his MBA from Golden Gate University.

Image of Reid M. Huber, Ph.D. Incyte Corporation’s Executive Vice President, Chief Scientific Officer

Reid M Huber, PhD

Executive Vice President, Chief Scientific Officer

Reid M. Huber joined Incyte as a member of the founding scientific team in January 2002 and has more than 17 years' experience in the pharmaceutical/biotech industry. For the past 13 years, Dr Huber has held roles of increasing responsibility across multiple therapeutic areas in both Drug Discovery and Clinical Development at Incyte. In 2011, Dr Huber assumed responsibility for the company's research activities as Senior Vice President, Discovery Biology. Before joining Incyte, Dr Huber held scientific research positions at DuPont and Bristol-Myers Squibb Company from 1998 to 2002. Dr Huber received his PhD in molecular genetics from the Washington University Medical School and held predoctoral and postdoctoral fellowships at the National Institutes of Health.

Image of Vijay Iyengar, MD. Incyte Corporation’s Executive Vice President, Global Strategy and Corporate Development

Vijay Iyengar, MD

Executive Vice President, Global Strategy and Corporate Development

Vijay Iyengar joined Incyte in May 2016 as Executive Vice President, Global Strategy and Corporate Development leading the company's Global Product Strategy, Business Development and Licensing, and Alliance Management teams. Dr Iyengar has more than 13 years of pharmaceutical industry experience, most recently serving as the President of Genoptix Corporation, a Novartis Company. At Genoptix, he led a 650-person organization focused on delivering CAP/CLIA certified oncology diagnostic testing as well as providing clinical trial assay development and execution services. Previously, Dr Iyengar held leadership roles in both U.S. and Global commercial functions at Novartis—he was Vice President and Rare Diseases Franchise Head at Novartis Oncology and Vice President and Oncology General Manager of Novartis Greece. Before joining Novartis in 2003, Dr Iyengar was an Engagement Manager at McKinsey & Company where he served pharmaceutical and medical device clients as part of their healthcare practice. Dr Iyengar received his Bachelor of Science degree in Biology from Stanford University and earned his MD from Harvard Medical School.

Image of Michael Morrissey, Incyte Corporate Senior Vice President, Head of Global Technical Operations

Michael Morrissey

Corporate Senior Vice President, Head of Global Technical Operations

Michael Morrissey joined Incyte in January 2016 as Corporate Senior Vice President and Head of Global Technical Operations. He has more than 30 years of global pharmaceutical industry experience through his prior positions in Research and Development, Quality Assurance, and Manufacturing. Most recently, Mr Morrissey served as Corporate Vice President, Head of International Technical Operations at Celgene International, where he built the company's internal production and distribution capabilities and launched Celgene's drugs worldwide. Prior to Celgene, he worked for Roche for 15 years in various positions. Mr Morrissey holds a diploma in Physics and Applied Mathematics from the University of London, United Kingdom.

Image of Maria E. Pasquale, Executive Vice President, General Counsel

Maria E. Pasquale

Executive Vice President, General Counsel

Maria E Pasquale joined Incyte in April of 2018 as Executive Vice President and General Counsel with nearly 20 years of legal, compliance, and intellectual property experience in the pharmaceutical industry. Ms Pasquale joined Incyte from Celgene Corporation, where for 17 years she held positions of increasing levels of responsibility including Chief Counsel; Senior Vice President, Legal and Deputy General Counsel and Assistant Corporate Secretary, where she was responsible for overseeing and managing Global Legal Departments including Intellectual Property, Regulatory, Litigation, Investigations and Transactional matters for Celgene's Corporate Headquarters and its over 50 wholly owned subsidiaries; and, most recently, Maria served as Celgene's Executive Vice President and Global Chief Compliance Officer, responsible for GxP and Healthcare Compliance globally. Prior to her tenure at Celgene, Ms Pasquale spent a decade supporting pharmaceutical clients as a global patent and litigation attorney at Pennie & Edmonds LLP in New York (now part of Jones Day). Before her career in law, Ms Pasquale was an Assistant Research Scientist at the Institute for Basic Research and the Cold Spring Harbor Laboratory, where she designed and implemented research projects in the areas of Alzheimer's Disease and oncology, respectively. Ms Pasquale holds a Juris Doctor Degree from Brooklyn Law School and a Bachelor of Science degree in biochemistry from the State University of New York at Stony Brook.

Image of Steven H. Stein, M.D., Incyte Corporation’s Senior Vice President, Chief Medical Officer

Steven H Stein, MD

Executive Vice President, Chief Medical Officer

Steven Stein joined Incyte as Senior Vice President and Chief Medical Officer in March 2015 and has over 10 years of experience in clinical development and regulatory interactions. Dr Stein joined Incyte from Novartis Pharmaceuticals Corporation, where he most recently served as Senior Vice President, US Clinical Development & Medical Affairs at Novartis Oncology US. Dr Stein previously worked at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. Dr Stein earned his MD from the University of the Witwatersrand in Johannesburg, South Africa.

Image of Paula J. Swain, Incyte Corporation’s Executive Vice President, Human Resources

Paula J Swain

Executive Vice President, Human Resources

Paula Swain joined Incyte in January 2002 and serves as Executive Vice President of Human Resources. Before joining the company, Ms Swain spent nearly 10 years with DuPont (acquired by Bristol-Myers Squibb Company in 2001), where she served as Vice President and Senior Vice President of Human Resources. She has also held human resource planning and employee relations positions with Chase Manhattan Bank, Marine Midland Bank, and Delaware Trust Company. Ms Swain received her BA in psychology from Rockhurst College and graduated from the strategic human resources planning program at Harvard Business School.

Image of Wenqing Yao, Ph.D. Incyte Corporation’s Executive Vice President, Discovery Medicinal and Process Chemistry

Wenqing Yao, PhD

Executive Vice President, Discovery Chemistry

Wenqing Yao joined Incyte in February 2002 as Director, Chemistry. Dr Yao has more than 20 years of experience in medicinal chemistry. For the past nine years, Dr Yao has held roles of increasing responsibility at Incyte, most recently as Senior Vice President, Discovery Chemistry. Before joining Incyte, Dr Yao held scientific research positions with DuPont and Bristol-Myers Squibb Company from 1996 to 2002. Dr Yao received his BS in chemistry from Xuzhou Normal University, his MS in organic chemistry from NanKai University, and his PhD in organic/medicinal chemistry from the University of Pennsylvania.

 

Board of Directors

HervÉ Hoppenot

Chairman, President,
and Chief Executive Officer,
Incyte Corporation

Julian C Baker

Managing Partner,
Baker Brothers Investments

Jean-Jacques BienaimÉ

Chief Executive Officer,
BioMarin Pharmaceutical, Inc.

Paul A Brooke

Founder and Former
Managing Director, venBio

Paul J Clancy

Chief Financial Officer,
Alexion Pharmaceuticals, Inc.

Wendy Dixon, PhD

Former Chief Marketing Officer
and President, Global Marketing,
Bristol-Myers Squibb Company

Jacqualyn A Fouse, PhD

Executive Chair, Dermavent Sciences

Paul A Friedman, MD

CEO and Chairman of the Board of Directors,
Madrigal Pharmaceuticals, Inc. and
Former President and Chief Executive
Officer, Incyte Corporation